Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627985 | 0.88 | ABAT (0.37) | LCKFYNDAOHPGDCES2 | |
| SCHEMBL11630985 | 0.82 | GRIK1 (0.38) | LCKFYNDAOHPGDCES2 | |
| SCHEMBL7391543 | 0.81 | POLB (0.47) | LCKFYNDAOHPGDCES2 | |
| SCHEMBL9251816 | 0.76 | CNR1 (0.54) | HDAC1KCNK3KCNK9 | |
| SCHEMBL5692310 | 0.75 | ALDH1A1 (0.44) | HPGDNPC1ABATCDC25ARAB9A | |
| SCHEMBL10337824 | 0.74 | ADRA2A (0.34) | NPC1 | |
| SCHEMBL25185645 | 0.74 | CTSS (0.38) | NPC1RAB9A | |
| SCHEMBL3280929 | 0.74 | — | — | |
| SCHEMBL41828 | 0.72 | ABAT (0.53) | HPGDNPC1L3MBTL1ABATCDC25A | |
| Hydrochloric Acid SCHEMBL3069393 | 0.72 | ABAT (0.53) | HPGDNPC1L3MBTL1ABATCDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661968-A | Antibacterial mildew-proof bamboo powder biodegradable material, preparation method thereof and application thereof in food packaging | 汕头市雷氏塑化科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | claimed |
| WO-2022128870-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | claimed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | claimed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5883075-A | HYPOTENSIVE AGENT CYCLIC PEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | claimed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | claimed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | claimed |
| EP-4747882-A1 | DATA STORAGE USING PROTEINS | The Hong Kong Polytechnic University (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | Fraunhofer-Gesellschaft Zur Forderung Der Angewanditen Forschung (DE) | 2026-01-27 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| EP-0061768-B1 | N-AMIDO SUBSTITUTED DIPEPTIDES | USV PHARMACEUTICAL CORPORATION (US) | 1986-05-14 | — | — | EP | disclosed |
| US-4127716-A | BACTERICIDE | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4088816-A | BACTERICIDES | E. R. SQUIBB & SONS, INC. (US) | 1978-05-09 | — | — | US | disclosed |
| US-3985740-A | THERAPEUTIC AND ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | LCK 648/4885FYN 1281/4885DAO 820/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | LCK 1130/4885FYN 2014/4885DAO 3623/4885 |
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | LCK 2929/4885FYN 3265/4885DAO 1407/4885 |
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | VIP, LNPEP, SARS1 | LCK 4019/4885FYN 4692/4885DAO 168/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | LCK 2929/4885FYN 3265/4885DAO 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.